Academic Title:
Assistant Professor
Primary Appointment:
Medicine
Administrative Title:
Director, Infectious Diseases Ambulatory Practice
Email:
Location:
725 West Lombard Street Baltimore, MD 21201
Phone (Primary):
410-706-3454
Education and Training
Undergrad: Miami University 2005
Medical school: Marshall University School of Medicine 2010
Clinical training: Marshall University Internal Medicine Residency 2013
University of Maryland Infectious Disease Fellowship 2016
Biosketch
My research interest is focused on clinical and translational surgical infectious diseases research with specific interest in Musculoskeletal infectious diseases (MSK ID). My interest in this aspect of infectious disease started when I was in fellowship at the University of Maryland. During that time, I helped conduct a longitudinal prospective study evaluating the use of adjuvant intraarticular antibiotics in the treatment of recalcitrant prosthetic joint infections. This allowed me to gain knowledge in prosthetic joint infection treatments and in surgical infectious disease in general. I subsequently joined as faculty at the University of Maryland to further conduct clinical and translational research in surgical infections. Over the past six years I have started to test novel therapeutics in the treatment of prosthetic joint infections. These include the use of bacteriophages to treat recalcitrant prosthetic joint infections as well as other novel therapeutics. I have devised novel protocols to apply these agents clinically and have a patent pending for a protocol to use bacteriophages in the treatment of prosthetic joint infections. Moreover, I am the PI on a multicenter prosthetic joint infection clinical trial using adjuvant phage therapy that will start in 2022.
As well, I have spearheaded a novel study evaluating the use of calcium sulfate biodegradable antibiotic beads in the treatment of vascular graft infections and I am currently leading a project to test a novel diagnostic alpha defensins in the diagnosis of nosocomial ventriculitis. Beyond these research projects, I have treated numerous patients in novel ways to reduce morbidity and prevent mortality in these patients and have published some of these case reports. In addition, I am developing a MSK ID multidisciplinary team/approach here at the University of Maryland with the orthopedic department to reduce moribidiy and moratlity in MSK ID patients. Lastly, I have formed strong collaborations Dr. Ken Urish at University of Pittsburgh and Dr. Ben Chan at Yale University as well as other investigators in the USA and in Europe.
Research/Clinical Keywords
Bacteriophage therapy; Periprosthetic joint infections; Musculoskeletal infections; Vascular graft infections; Neurosurgical infections; Surgical infections
Highlighted Publications
1. Doub JB, Urish K, Lee M, Fackler J. Impact of Bacterial Phenotypic Variation with Bacteriophage therapy: A Pilot Study with Prosthetic Joint Infection Isolates [published online ahead of print, 2022 Mar 21]. Int J Infect Dis. 2022;S1201-9712(22)00161-8. doi:10.1016/j.ijid.2022.03.022
2. Doub JB, Wilson E. Observed transaminitis with a unique bacteriophage therapy protocol to treat recalcitrant Staphylococcal biofilm infections. Infection. 2022;50(1):281-283. doi:10.1007/s15010-021-01675-w
3. DePalma BJ, Nandi S, Chaudhry W, Lee M, Johnson AJ, Doub JB. Assessment of Staphylococcal Clinical Isolates from Periprosthetic Joint Infections for Potential Bacteriophage Therapy. J Bone Joint Surg Am. 2022 Feb 15. doi: 10.2106/JBJS.21.00958. Epub ahead of print.
4. Doub JB, Ng VY, Johnson AJ, Slomka M, Fackler J, Horne B, Brownstein MJ, Henry M, Malagon F, Biswas B. Salvage Bacteriophage Therapy for a Chronic MRSA Prosthetic Joint Infection. Antibiotics (Basel). 2020 May 9;9(5):241.
5. Doub JB. Risk of Bacteriophage Therapeutics to Transfer Genetic Material and Contain Contaminants Beyond Endotoxins with Clinically Relevant Mitigation Strategies. Infect Drug Resist. 2021 Dec 23;14:5629-5637.
6. Doub JB, Bork JT, Heil E, Stafford K, Banoub M, Karwowski JK, Toursavadkohi S. Effectiveness and Safety of Biodegradable Calcium Sulfate Antibiotic Beads as Adjuvant Therapy in Vascular Graft Infections. Open Forum Infect Dis. 2021 Jan 4;8(2):ofaa650.
7. Doub JB, Ng VY, Johnson A, Amoroso A, Kottilil S, Wilson E. Potential Use of Adjuvant Bacteriophage Therapy With Debridement, Antibiotics, and Implant Retention Surgery to Treat Chronic Prosthetic Joint Infections. Open Forum Infect Dis. 2021 May 26;8(6):ofab277.
8. Doub JB. Bacteriophage Therapy for Clinical Biofilm Infections: Parameters That Influence Treatment Protocols and Current Treatment Approaches. Antibiotics (Basel). 2020;9(11):799. Published 2020 Nov 12. doi:10.3390/antibiotics9110799
Additional Publication Citations
Research Interests
Bacteriophage therapy
Musculoskeletal infections
Ventriculitis
Vascular graft infections
Novel therapeutics
Awards and Affiliations
2010 Alpha Omega Alpha Honor Medical Society
2010 Lake Poland Award (4.0 G.P.A. through medical school), Marshall
University School of Medicine
2014 Teaching Attending of the Year, Marshall University School of Medicine
2020 Infectious Disease Teaching Attending of the Year, University of Maryland
School of Medicine
2021 Baltimore Top Doctors, Baltimore Magazine
Grants and Contracts
Active grants
9/2022-9/2026 Ken Urish (MPI) and James B. Doub (MPI)
NIAMS RO1 AR082167
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase I/II Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection
4/2024-3/2026 Ashley Levack and James Doub (MPI)
NIAMS R21 AR084183-01
The utility of bacteriophage therapy in fracture-related infections: Preclinical research needed to create effective and reproducible treatment protocols
12/1/2023-11/30/2024 James B Doub (PI)
UMB ICTR/CTSA 1UL1TR003098
Rescue of bacteriophage activity against synovial fluid bacterial aggregates
Pending Grants:
12/2024-11/2026 Ken Urish (MPI) and James Doub (MPI)
NIAMS R21 AI188355-01
Preclinical Research to Determine Prosthetic Joint Infection Pathophysiology Needed to Direct Clinical Bacteriophage Therapy
4/1/2025-3/31/2030 Ken Urish (MPI) and James Doub (MPI)
NIAID R01 AI189525-01
Changes in Staphylococcus aureus Pathogenesis Following Exposure to Bacteriophages During the Clinical Treatment of Periprosthetic Joint Infections
Completed Grants
12/1/2021-11/30/2022 James B Doub (PI)
UMB ICTR/CTSA 1UL1TR003098
Determining effectiveness of Minocycline Suppression Antibiotics in hardware Infections
12/1/2022-11/30/2023 James B. Doub (PI)
UMB ICTR/CTSA 1UL1TR003098
Location of biofilms on infected prosthetic joint infections
In the News
Dr. Doub was named a "Top Doctor" by Baltimore Magazine in 2021
https://www.medscape.com/viewarticle/969001
https://ryortho.com/breaking/could-a-virus-eradicate-peri-prosthetic-biofilm-infections